Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension
- PMID: 15031263
- DOI: 10.1161/01.RES.0000126050.41296.8E
Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension
Abstract
Severe pulmonary hypertension is a disabling disease with high mortality. We investigated acute and chronic effects of iloprost, a long-acting prostacyclin analogue, and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in monocrotaline-induced pulmonary hypertension in rats. Twenty-eight and 42 days after administration of the alkaloid, right ventricular systolic pressure increased from 25.8+/-2.0 to 62.9+/-3.4 and 70.5+/-7.4 mm Hg, with concomitant decline in cardiac index, central venous oxygen saturation, and arterial oxygenation. Marked right heart hypertrophy was demonstrated by the strongly elevated ratio of right ventricle/left ventricle plus septum weight, and massive thickening of the precapillary artery smooth muscle layer was shown histologically. Western blot analysis demonstrated increased levels of matrix metalloproteinases (MMPs) -2 and -9 and increased gelatinolytic activities in isolated pulmonary arteries. In these animals, both intravenous iloprost and tolafentrine displayed characteristic features of pulmonary vasodilators. When chronically infused from days 14 to 28, both agents significantly attenuated all monocrotaline-induced hemodynamic and gas exchange abnormalities as well as right heart hypertrophy. Full normalization of all variables including right ventricle size was achieved on combined administration of both agents during this period. This was also true for MMP-2 and MMP-9 expression and activity. Moreover, when iloprost plus tolafentrine was used for late therapeutic intervention, with infusion from days 28 to 42 after full establishment of severe pulmonary hypertension and cor pulmonale, hemodynamic, gas exchange, and cardiac and pulmonary vascular remodeling changes were significantly reversed. We conclude that the combined administration of iloprost and a dual-selective phosphodiesterase 3/4 inhibitor prevents and reverses the development of pulmonary hypertension and cor pulmonale in response to monocrotaline in rats. This regimen may therefore offer a possible antiremodeling therapy in severe pulmonary hypertension.
Similar articles
-
Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.Cardiovasc Res. 2009 Apr 1;82(1):30-9. doi: 10.1093/cvr/cvp002. Epub 2009 Jan 8. Cardiovasc Res. 2009. PMID: 19131365
-
Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity.Am J Respir Crit Care Med. 2001 Nov 1;164(9):1694-700. doi: 10.1164/ajrccm.164.9.2105060. Am J Respir Crit Care Med. 2001. PMID: 11719312
-
Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats.Am J Respir Crit Care Med. 2004 Jan 1;169(1):39-45. doi: 10.1164/rccm.200302-282OC. Epub 2003 Sep 4. Am J Respir Crit Care Med. 2004. PMID: 12958054
-
Cellular pathophysiology and therapy of pulmonary hypertension.J Lab Clin Med. 2001 Dec;138(6):367-77. doi: 10.1067/mlc.2001.119285. J Lab Clin Med. 2001. PMID: 11753283 Review.
-
Iloprost for idiopathic pulmonary arterial hypertension.Expert Rev Cardiovasc Ther. 2005 Mar;3(2):215-23. doi: 10.1586/14779072.3.2.215. Expert Rev Cardiovasc Ther. 2005. PMID: 15853595 Review.
Cited by
-
Does cyclically iloprost infusion prevent severe isolated pulmonary hypertension in systemic sclerosis? Preliminary results.Rheumatol Int. 2006 Dec;27(2):203-5. doi: 10.1007/s00296-006-0222-4. Epub 2006 Sep 28. Rheumatol Int. 2006. PMID: 17006704 Clinical Trial.
-
Pulmonary Hypertension-Associated Right Ventricular Cardiomyocyte Remodelling Reduces Treprostinil Function.Cells. 2023 Dec 4;12(23):2764. doi: 10.3390/cells12232764. Cells. 2023. PMID: 38067192 Free PMC article.
-
The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats.PLoS One. 2012;7(8):e43433. doi: 10.1371/journal.pone.0043433. Epub 2012 Aug 17. PLoS One. 2012. PMID: 22912874 Free PMC article.
-
Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.Respir Res. 2006 Jan 19;7(1):9. doi: 10.1186/1465-9921-7-9. Respir Res. 2006. PMID: 16423283 Free PMC article.
-
Levosimendan attenuates pulmonary vascular remodeling.Intensive Care Med. 2011 Aug;37(8):1368-77. doi: 10.1007/s00134-011-2254-9. Epub 2011 May 31. Intensive Care Med. 2011. PMID: 21626431 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous